Real-world efficacy of switching androgen receptor signaling inhibitor therapy following apalutamide discontinuation because of adverse events in advanced prostate cancer: a multicenter study
This real-world multicenter analysis demonstrated that approximately one in seven patients with prostate cancer discontinued apalutamide treatment because they developed rashes. However, switching to other ARSIs preserved oncological outcomes, with no significant differences in PFS, MFS, or OS observed, regardless of prostate cancer subtype. Therefore, this type of switching does not appear to compromise subsequent treatment efficacy if it is done while the disease remains sensitive to ARSIs.
Authors
- Homare Okazoe
- Yoichiro Tohi (ORCID: https://orcid.org/0000-0003-3884-8915)
- Tomohiro Mashima
- Rikiya Taoka
- Hiromi Hirama (ORCID: https://orcid.org/0000-0003-1047-5002)
- Isaku Nomura
- Yuki Matsuoka (ORCID: https://orcid.org/0000-0001-5999-3922)
- Hirohito Naito (ORCID: https://orcid.org/0000-0002-1045-1978)
- Hironobu Arai
- Hiroyuki Tsunemori (ORCID: https://orcid.org/0000-0002-8016-2928)
- M. Sugimoto
- Nobuyoshi Yamaoka
- Kana Kohashiguchi
- Yohei Abe (ORCID: https://orcid.org/0000-0003-2519-4924)
- Kengo Fujiwara (ORCID: https://orcid.org/0000-0002-2611-5266)
- Yushi Hayashida
- Toshifumi Yano
- Nobufumi Ueda
- Takuma Kato
Institutions
- Obayashi (Japan) (JP)
- Hiroshima Shudo University (JP)
- Kagawa University (JP)
- Mizushima Central Hospital (JP)
- Sakai Municipal Hospital (JP)
- Morinomiya Hospital (JP)
- Kagawa Prefectural Central Hospital (JP)
- Shikoku Research Institute (JP)
- National Hospital Organization Takamatsu Medical Center (JP)
Publication Details
- Journal
- Japanese Journal of Clinical Oncology
- Published
- 2025-12-09
- DOI
- https://doi.org/10.1093/jjco/hyaf205
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00